Robert J. Gould's most recent trade in Fulcrum Therapeutics Inc was a trade of 36,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Fulcrum Therapeutics Inc | Robert J. Gould | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2025 | 36,000 | 36,000 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Turnstone Biologics Corp | Robert J. Gould | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 12,770 | 12,770 | - | - | Stock Option (Right to Buy) | |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director, Interim President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director, Interim President & CEO | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 13 Jan 2023 | 6,766 | 499,864 (2%) | 0% | 15 | 101,490 | Common Stock |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2022 | 19,000 | 19,000 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director | Sale of securities on an exchange or to another person at price $ 8.09 per share. | 07 Jun 2022 | 71,435 | 506,630 (2%) | 0% | 8.1 | 577,895 | Common Stock |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2022 | 71,435 | 86,523 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 07 Jun 2022 | 71,435 | 578,065 (2%) | 0% | 7.8 | 560,050 | Common Stock |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2022 | 25,551 | 182,340 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director | Sale of securities on an exchange or to another person at price $ 7.95 per share. | 02 Jun 2022 | 25,551 | 506,630 (2%) | 0% | 7.9 | 203,056 | Common Stock |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 02 Jun 2022 | 25,551 | 532,181 (2%) | 0% | 7.8 | 200,320 | Common Stock |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2022 | 24,382 | 157,958 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director | Sale of securities on an exchange or to another person at price $ 8.10 per share. | 02 Jun 2022 | 24,382 | 506,630 (2%) | 0% | 8.1 | 197,592 | Common Stock |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 02 Jun 2022 | 24,382 | 531,012 (2%) | 0% | 7.8 | 191,155 | Common Stock |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director | Sale of securities on an exchange or to another person at price $ 7.92 per share. | 02 Jun 2022 | 16,689 | 506,630 (2%) | 0% | 7.9 | 132,162 | Common Stock |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2022 | 16,689 | 207,891 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 02 Jun 2022 | 16,689 | 523,319 (2%) | 0% | 7.8 | 130,842 | Common Stock |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 07 Apr 2022 | 5,631 | 512,261 (2%) | 0% | 7.8 | 44,147 | Common Stock |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2022 | 5,631 | 224,580 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director | Sale of securities on an exchange or to another person at price $ 24.01 per share. | 07 Apr 2022 | 5,631 | 506,630 (2%) | 0% | 24.0 | 135,228 | Common Stock |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director | Sale of securities on an exchange or to another person at price $ 24.26 per share. | 01 Apr 2022 | 52,552 | 506,630 (2%) | 0% | 24.3 | 1,274,775 | Common Stock |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 01 Apr 2022 | 52,552 | 559,182 (2%) | 0% | 7.8 | 412,008 | Common Stock |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 52,552 | 230,211 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 34,464 | 289,998 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 01 Apr 2022 | 34,464 | 541,094 (2%) | 0% | 7.8 | 270,198 | Common Stock |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director | Sale of securities on an exchange or to another person at price $ 24.03 per share. | 01 Apr 2022 | 34,464 | 506,630 (2%) | 0% | 24.0 | 828,160 | Common Stock |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director | Sale of securities on an exchange or to another person at price $ 24.02 per share. | 01 Apr 2022 | 7,235 | 506,630 (2%) | 0% | 24.0 | 173,749 | Common Stock |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 01 Apr 2022 | 7,235 | 513,865 (2%) | 0% | 7.8 | 56,722 | Common Stock |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 7,235 | 282,763 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 12.13 per share. | 15 Mar 2021 | 9,211 | 507,419 (2%) | 0% | 12.1 | 111,773 | Common Stock |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 12.43 per share. | 15 Mar 2021 | 789 | 506,630 (2%) | 0% | 12.4 | 9,806 | Common Stock |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 14.19 per share. | 16 Feb 2021 | 6,542 | 518,303 (2%) | 0% | 14.2 | 92,830 | Common Stock |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 14.56 per share. | 16 Feb 2021 | 1,673 | 516,630 (2%) | 0% | 14.6 | 24,367 | Common Stock |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 269,390 | 269,390 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Robert J. Gould | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 12.08 per share. | 20 Jan 2021 | 10,000 | 524,845 (2%) | 0% | 12.1 | 120,826 | Common Stock |